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A novel caspase 8 selective small 
molecule potentiates TRAIL-
induced cell death
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Chamila Rupasinghe2, Jérémie Roux3, Stefan Andrei1, Bingqian Guo2, Alexandra Panaitiu2, 
Maria Pellegrini2, Dale F. Mierke2 & Roya Khosravi-Far1, 5
Recombinant soluble TRAIL and agonistic antibodies against TRAIL receptors (DR4 and DR5) are 
currently being created for clinical cancer therapy, due to their selective killing of cancer cells 
and high safety characteristics. However, resistance to TRAIL and other targeted therapies is an 
important issue facing current cancer research field. An attractive strategy to sensitize resistant 
malignancies to TRAIL-induced cell death is the design of small molecules that target and promote 
caspase 8 activation. For the first time, we describe the discovery and characterization of a small 
molecule that directly binds caspase 8 and enhances its activation when combined with TRAIL, but 
not alone. The molecule was identified through an in silico chemical screen for compounds with 
affinity for the caspase 8 homodimer’s interface. The compound was experimentally validated to 
directly bind caspase 8, and to promote caspase 8 activation and cell death in single living cells or 
population of cells, upon TRAIL stimulation. Our approach is a proof-of-concept strategy leading to 
the discovery of a novel small molecule that not only stimulates TRAIL-induced apoptosis in cancer 
cells, but may also provide insights into the structure-function relationship of caspase 8 homodimers 
as putative targets in cancer.
Apoptotic cell death is a mean to eliminate unwanted or damaged cells1–3. Caspase 8 is a cysteine protease 
that initiates a cell death response mediated by a group of receptors of the tumor necrosis factor (TNF) 
superfamily, including TRAIL, commonly known as death receptors1,4. Dysregulation of the apoptotic 
process makes cancer cells resistant to TRAIL and conventional therapies. Apo2L/TRAIL is a cytokine 
known for its potential to selectively kill cancer cells and it is an important candidate for targeted cancer 
therapy. However, many cancer cells show resistance to TRAIL-induced apoptosis and efficient strategies 
for sensitization to TRAIL have to be developed3. The apoptosis process is triggered by recruitment of 
adaptor proteins, such as FAS-associated death domain (FADD), to the death receptors, which is followed 
by recruitment of caspase 8 pro-enzyme. This causes dimerization of caspase 8 resulting in its activation. 
This death receptor recruitment process also brings a variety of other proteins to the death-inducing sig-
naling complex (DISC)1,5,6, which forms within biologically important and dynamic membrane domains 
named lipid rafts7.
Among the proteins recruited to the DISC is cellular FLICE-like inhibitory protein, long isoform 
(FLIPL)8. cFLIPL is homologous to caspase 8 but has a pseudocaspase domain which lacks catalytic res-
idues9. Caspase 8-cFLIP heterodimers are formed at the DISC, when FADD recruits both FLIP and 
caspase 8 to its cytoplasmic tails. Active caspase 8 generated from an efficient DISC can be inhibited by 
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high levels of c-FLIP, antagonizing caspase 8 activation. Although cFLIP inhibits apoptotic activation of 
caspase 8, caspase 8-cFLIP heterodimer complexes intriguingly may possess catalytic activity10. In vitro 
and structural studies suggest that the formation of caspase 8-cFLIP heterodimers is favored over caspase 
8 homodimers, as cFLIP has a greater affinity for pro-caspase 8 than for itself10. The crystal structure of 
the protease-like domain of cFLIPL in complex with zymogen caspase 8 reveals insights into the favorable 
heterodimerization complex over the pro-caspase 8 homodimerization11. Heterodimerization constrains 
the active site of zymogen caspase 8 into a productive conformation, resulting in proteolysis of a number 
of local substrates such as RIP12, even in the absence of the interdomain autocleavage events that are 
necessary for stabilization and activity of caspase 8 homodimer10–12. Noteworthy, although cFLIPL can 
initiate the first proteolytic cleavage of pro-caspase 8, it also prevents subsequent cleavage of caspase 8. 
Activation of caspase 8 induced by caspase 8-cFLIP heterodimer is different from activation occurring in 
the pro-caspase 8 homodimer, resulting only in partial activation of caspase 8, which is restricted to the 
cellular membrane13. Thus, pro-caspase 8 homodimers, resulting in an increase in the mature caspase 8 
homodimers, are needed to induce fast and efficient apoptosis.
Numerous caspase inhibitors targeting the active sites of caspases have been developed. The pocket at 
the caspase dimerization interface of caspases has also been successfully targeted with the goal to identify 
novel inhibitors. Structural studies of the caspase 7 dimer interface using disulfide trapped inhibitors 
reversed the structural transition and induced a structural conformation that was almost indistinguish-
able from the zymogen form14. By using caspase 1, it has been shown that a general allosteric binding 
site for reversing the caspase activation with small molecules exists15. All of these inhibitors block the 
apoptotic process. However, instead of inhibiting caspases it would be of considerable medical interest 
to activate them and induce caspase-dependent cell death in cancer cells, tissue and tumors that are 
resistant to apoptosis.
We therefore developed and employed an innovative strategy to discover novel small molecules 
that would bind at the caspase 8 interface and stabilize the caspase 8 homodimers. The role of cleav-
age in caspase 8 activation is complex. Pro-caspase 8, an inactive precursor or zymogen, undergoes 
major structural transitions after auto- or trans-proteolysis, which results in interdomain cleavages in a 
defined order, yielding mature caspase 8, containing two large and two small subunits. Structural studies 
have shown that the β6-strand dimerization interface of mature caspase 8/zymogen caspase 8 homod-
imers have reduced hydrogen bonding capacity compared to zymogen caspase 8-cFLIP heterodimer11. 
The formation of the zymogen caspase 8 homodimer is further obstructed by the presence of the L2 
loops11. If pro-caspase 8 homodimerization could be favored by additional stabilization or interaction, 
it would result in a productive conformation that is able to initiate faster and more efficient auto- or 
trans-proteolysis, resulting in mature caspase 8 homodimers. This could result in enhanced initiator 
caspase activation and caspase 8 activity. In order to identify small molecules with affinity for the caspase 
8 homodimeric interface, we carried out a virtual screening using a library of 3,000 small molecules. 
The best hits were experimentally validated in a series of binding and activation assays. One of the small 
molecules identified demonstrated activity both in cancer cells that are resistant and cancer cells that are 
sensitive to caspase-dependent cell death induced by TRAIL. These results taken in sum provide insight 
into the structure-function relationship of caspase 8 homodimers as a putative target in drug strategies 
for targeting cancer.
Materials and Methods
In silico identification of the small molecules. The Virtual Screening (VS) was carried out using 
AutoDock Suite 4.0.116. In short, the protease-like domain of pro-caspase 8 (PDB ID: chain B of 3H11) 
was used as the target receptor. A library of 3,000 small molecules (Life Chemicals Inc.) was targeted 
against pro-caspase 8. Hydrogen atoms were included into all 3D coordinates of the receptor and the 
ligands. Atomic charges were set for the ligands and the receptor using AutoDock Tools 1.5.4. All bonds 
of the ligands were considered as flexible and the receptor was kept rigid. A grid center was introduced, 
which functioned as the starting point in the search space. AutoGrid 4.0.1 was carried out to generate 
the map files for the flexible atoms. The docking parameter file (DPF) was defined with the Genetic algo-
rithms (either Lamarkian genetic algorithm or Hybrid genetic algorithm), maximum number of energy 
evaluations, initial population, number of runs and maximum RMS tolerance for conformational cluster 
analysis. DPF was generated using the map files and 3D coordinates files with atom charges. AutoDock 
4.0.1 was applied for the ligand library. During the search process, binding energies were calculated con-
sidering non-bonded interactions (Van-de Walls and electrostatic interactions), H-bonding, desolvation 
and torsional energy of the complexes. Finally, the binding results were sorted according to the minimum 
binding energy for the best pose and the conformation of the ligand on the binding site i.e., the lowest 
energy conformation from the largest cluster chosen as representative. Top hits were selected for further 
molecular and cellular experimental analysis.
Molecular modeling of the Caspase 8 / Compound 2 complex. Homology model for zymogen 
caspase 8 monomer 1 was built using PDB ID: 3H11_chain B as the template (89% sequence iden-
tity) using SWISS MODEL16,17. Compound 2 was docked into the dimer interface of monomer 1 using 
AutoDock 4.0118 to identify the mode of binding. The caspase 8 homodimer (with monomers 1 & 2) 
was generated using the X-ray structure 3H11 as a guide for the placement of monomer 2. The resulting 
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complex was then relaxed by energy minimization using steepest descent followed by conjugate gradient 
for 400 steps using UCSF Chimera 1.8.119.
Protein production. The FADD sequence 1-191 was cloned in a modified pET21 vector with a 
C-terminal hexa-histidine tag and expressed in Rosetta-gami 2 DE3 pLysS cells at 32 °C overnight. Cells 
were lysed using a French Press and the whole lysate was denatured in 8 M urea. After centrifugation, 
the supernatant was applied to a HisTrap column (GE Healthcare) and the protein was refolded on col-
umn. The protein was then concentrated and purified by size exclusion chromatography (SEC) using a 
Superdex75 16/60 column (GE Healthcare).
The DNA for the GST-caspase 8 fusion protein was a gift from Dr. M. E. Peter (Northwestern 
University). The 80 kDa protein was expressed in the E. coli strain BL21 (DE3). Cultures were grown at 
37 °C in Terrific Broth, induced with 0.2 mM IPTG and transferred to 20 °C for 16-18 hours. The pro-
tein formed inclusion bodies, which were washed four consecutive times in buffer containing either 2% 
Deoxycholate or 0.2% Triton X-100, then washed twice in buffer without surfactants. Finally, the clean 
inclusion bodies were resolubilized in 8 M Urea, 50 mM Tris-HCl, pH = 8.0 and the protein was refolded 
through successive rounds of dialysis in the presence of additives (2 mM DTT, 10% glycerol, 100 mM 
L-Arginine).
cFLIP DNA was cloned into pET21b+, and the protein was expressed with a C-terminal hexa-histidine 
tag. The protein expressed in the Rosetta (DE3) pLysS strain after induction with 0.2 mM IPTG and over-
night incubation at 32 °C. The protein was resolubilized out of the pellet in 8 M urea, 50 mM Tris-HCl, 
500 mM NaCl, pH = 8.0 and purified on Ni-NTA resin under denaturing conditions. Refolding was 
achieved through successive rounds of dialysis in 50 mM Tris-HCl, 150 mM NaCl, 5% glycerol, 0.2% 
NP40, 1 mM DTT, pH = 8.0.
The cytoplasmic domain of DR5 was cloned into pGEX-4T1 between the BamHI and EcoRI restriction 
sites. The GST-fusion protein was expressed in E. Coli BL21 (DE3) as described above and purified using 
a GSTrap column (GE Healthcare) followed by SEC on a Superdex 75 16/60 column (GE Healthcare).
STD-NMR binding analysis. NMR experiments were carried out on a Bruker 700 MHz spectrometer 
equipped with a TCI cryoprobe, at 25 °C. The STD-NMR experiments19 utilized water suppression by 
excitation sculpting20 and interleaved acquisition of on- and off-resonance spectra (saturation at 0 Hz 
and −2000 Hz respectively). Saturation was achieved by a cascade of 50 ms Gaussian pulses for a period 
of 3 sec. A spin-lock period of 15 ms was applied to suppress residual protein resonances. 32k points and 
256 transients were acquired for each experiment. Lorentzian broadening (0.3 Hz) was applied before 
Fourier transform.
Each sample contained the target protein (2 μM for caspase 8 or cFLIP, 10 μM for DR5, 5 μM for 
FADD, 3 μM for the GST-tag) and 200 μM of the small molecule tested. The caspase 8 samples utilized 
50 mM phosphate buffer, pH 7.5, 250 mM NaCl, 5% D2O (deuterium oxide).
Saturation transfer from the protein to the bound small molecules causes a decrease in the intensity 
of the small molecule resonances, which is detected as residual signal in a difference spectrum.
Cell lines and cell culture reagents. K562, Jurkat and PC3 cell lines were purchased from ATCC. 
These cell lines were grown in RPMI 1640 medium (Mediatech Inc., VA, USA, Cat. # 10-040-CV) supple-
mented with 10% fetal bovine serum (FBS, HyClone, Cat. # SH30088.03), 2 mM L-glutamine (Mediatech, 
Cat. # 25-005-CI) and 100 units/ml Penicillin/ 100 μg/ml Streptomycin (Mediatech Inc., Cat. # 30-001-CI).
HeLa cells were obtained from the ATCC and cultured in DMEM (Mediatech Inc., VA, USA) sup-
plemented with 10% fetal bovine serum, 5 mM L-glutamine and 100 units/ml Penicillin/ 100 μg/ml 
Streptomycin. HeLa cells stably expressing combinations of IC-RP (caspase 8 activity reporter), and 
IMS-RP (Mitochondrial Outer Membrane Permeabilization (MOMP) reporter) were derived by infection 
with Adenovirus, followed by double positive selection by flow cytometric analysis. Sorted single cells 
were grown in 96-well plates until apparition of colonies. Cells were passed every 2-3 days and used in 
experiments during their logarithmic growth phase.
Reagents. Compound 1 (3-Morpholin-4-yl-1-[5-(3-nitro-phenyl)-3-phenyl-4,5-dihydro-pyrazol-
1-yl]-propan-1-one), Compound 2 (3-Cyclopropyl-6-[4-(2-phenyl-ethenesulfonyl)-piperazin-
1-yl]-[1,2,4]triazolo[4,3-b]pyridazine) and Compound 3 (1-(2-Indol-1-yl-acetyl)-piperidine-4-carboxylic 
acid (5-methyl-isoxazol-3-yl)-amide) were provided by Spoluka Chemical Company (aka Life Chemicals, 
Inc., Kiev, Ukraine). Compound 4 (1-Azaxanthone; 5H-chromeno[2,3-b]pyridin-5-one) was provided by 
Maybridge (Cornwall, England). The compounds were used at 20, 40 or 80 μM (initial testing was done 
with concentrations ranging between 5 μM-320 μM).
Recombinant human (rh) TRAIL was a kind gift of Dr. Carlos Reis (University of Groningen, the 
Netherlands)21,22. TRAIL was used at 7.5 ng/ml (Jurkat), 10 ng/ml (PC3) and 45-100 ng/ml (K562).
Suspension cells (K562 and Jurkat) were counted and plated at specific concentrations in 24 well plates 
or 6 well plates, followed by the treatment with DMSO, TRAIL, the compounds and the combination for 
8-28 h in 0.5-1% FBS (see the figure legends for specific details).
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Reporter constructs. Caspase 8 activity reporter (IC-RP) and Mitochondrial Outer Membrane 
Permeabilization (MOMP) reporter (IMS-RP) were constructed as previously described23.
Viability / cell death analysis (automated trypan blue exclusion assay). Viability and cell death 
was quantified by using an automated Trypan blue exclusion method as previously described24. BioRad 
TC10 automated cell counter is designed to count Trypan blue positive and negative suspended cells and 
can determine viability by an automated image analysis algorithm with high reproducibility when the 
concentration of cells is within 5 × 104–107 cells/ml. Briefly, after collection of the suspension (K562 and 
Jurkat) or adherent cells (PC3), a volume of 30-40 μl of cells was mixed with an equal volume of Trypan 
Blue solution (0.4%). 10 μl of this mix was then loaded on a special counting chamber and read with 
the BioRad TC10 cell counter after 10 seconds. For adherent cells, PC3 cells were washed with DPBS 
(Mediatech, Inc, Cat. # 21-031-CV) and collected by using Trypsin EDTA (0.25% Trypsin / 2.21 mM 
EDTA in HBSS; Mediatech, Inc., Cat. # 25-053-CI). Each experiment was repeated three times, except 
if indicated otherwise. For every experiment, each treatment was performed in duplicate and multiple 
readings were performed for each condition.
Western blotting. Cells were washed with PBS and lysed in RIPA buffer (Boston BioProducts, 
Boston, USA, Cat. # BP-115D). SDS-PAGE and the immunoblotting were performed as previously 
described25,26. Whole cell lysates (30 μg) in reducing Laemmli’s SDS Sample Buffer (Boston Bioproducts, 
Cat # BP-110R) were resolved by 10% SDS-PAGE, and transferred to 0.45 μm Immobilon PVDF mem-
branes (Millipore, MA, USA Cat # IPVH00010). The membranes were then blocked for 30 min at room 
temperature in blocking buffer (5% w/v non-fat dry milk/Tris-buffered saline-Tween-20) (TBST: 50 mM 
Tris-HCl (pH 7.4), 150 mM NaCl, 0.05% (v/v) Tween-20). Rabbit/mouse primary antibodies were diluted 
in 5% (w/v) blocking buffer then incubated with membranes overnight at 4 °C, or for 2 h at room tem-
perature. Membranes were then washed three times with TBST, incubated for 1 h at room tempera-
ture with either HRP-conjugated goat anti-mouse or goat anti-rabbit IgG secondary antibodies (sc-2055 
and sc-2054, respectively, Santa Cruz Biotechnology, CA, USA) diluted 1: 3500-4000 in blocking buffer, 
and then washed again with TBST prior to visualization using a chemiluminescent substrate (Pierce 
ECL Western Blotting Substrate, Super Signal West Pico or Super Signal West Femto, Pierce - Thermo 
Scientific, IL, USA).
Most of the antibodies employed for probing the Immobilon PVDF membranes were purchased from 
Cell Signaling Technology (MA, USA) and used at dilution of 1:1,000-1,500: PARP (# 9542), caspase 3 
(# 9662), cleaved caspase 3 (# 9664), caspase 8 (# 9746), cleaved caspase 8 (# 9496), caspase 9 (# 9502), 
IKappaBα (# 9242). Anti-β-Actin antibody (clone AC-15) (# A5441) was purchased from Sigma (MO, 
USA) and used at a dilution of 1:20,000.
Photomicrograph and image processing. Phase contrast / bright field microscope images were 
taken using a Nikon Eclipse TI-S Inverted Microscope (4x or 10x objective lenses) and by using QCapture 
2.99.5 software (2009, Quantitative Imaging Corporation).
Live-Cell Microscopy and image analysis of single cells. Time-lapse microscopy movies were 
recorded with a Deltavision fluorescence microscope equipped with an environmental chamber 
(Olympus, Applied Precision) at 10x magnification with frames every 3 minutes for 24 hours. Cells grown 
in 8-well chambered cover glass slides (Nunc) were shifted into phenol red-free medium (Invitrogen) 
supplemented with 10% fetal bovine serum and L-glutamine for imaging. For FRET signal analysis, ratio 
of background-subtracted CFP and YFP images were created by using ImageJ and custom plug-ins23. 
Signals were normalized by subtracting the minimum value across all time points from each single-cell 
time course. IMS-RP release in cell cytoplasm was analyzed in ImageJ by visual inspection, which ena-
bled an identification of the first frame of IMS-RFP release and subsequent time of cell death of each 
single-cell of the cell population analyzed.
Results
In silico identification of the small molecules that bind caspase 8 and experimentally sensi-
tize Jurkat cells to TRAIL-induced apoptosis. Small molecules that can activate caspase 8 and/or 
sensitize resistant cells to death ligands-induced cell death have the potential to become an exciting class 
of novel pro-apoptotic cancer therapies. We designed an in silico screening to identify for the first time 
small molecules that bind caspase 8 and stabilize the zymogen caspase 8 homodimerization, resulting in 
a productive caspase 8 conformation that initiates faster processing of mature caspase 8.
We targeted the zymogen caspase 8 interface region formed by the small subunit (purple, Fig. 1A): 
by first generating a model of the zymogen caspase 8 structure based on the X-ray structure of zymo-
gen caspase 8 (lacks L2 loop region) in complex with cFLIPL (PDB ID: 3H13) and then using it for in 
silico molecular docking studies. The top four compounds resulting from the in silico screening (labeled 
as C1-C4 in Fig. 1B,C) were then experimentally tested in Jurkat cells for their potential to induce cell 
death alone or in combination with the death ligand Apo2L/TRAIL (Fig. 1B). Jurkat cells were treated 
with DMSO (control), TRAIL, compounds 1-4 and the combination, for 24 h. Results show that all four 
compounds sensitize Jurkat cells to TRAIL-induced cell death, with compounds 2 and 3 being the most 
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effective. Compound 1 can also induce significant cell death when used alone (Fig. 1C). A predicted 3D 
conformation of the hit compounds bound to the caspase 8 interface region, as derived from the docking 
effort, is depicted in Fig. 1D.
Small molecule compound 2 directly binds caspase 8. In order to determine if the four com-
pounds that sensitize Jurkat cells to TRAIL-induced cell death are indeed directly binding caspase 8, we 
performed saturation transfer difference (STD)-NMR experiments (Fig. 2). We tested the molecules for 
binding to caspase 8 and three additional components of the DISC as a control: Death Receptor 5 (DR5), 
cFLIP and FADD. The NMR spectrum of compound 2 in the presence of caspase 8 shows pronounced 
line broadening due to the direct interaction with the high molecular weight caspase 8 and slower tum-
bling in solution (Fig. 2A). No line broadening was observed in the control experiments in presence of 
the GST fusion protein alone (Fig. 2B), or buffer alone (Fig. 2C). Compound 1 and compound 4 display 
no line broadening and a small residual signal in STD-NMR experiments, evidence of very weak bind-
ing to caspase 8. Compound 3 does not show binding to caspase 8, within the affinity ranged sampled 
by STD-NMR (μM-mM). In our STD-NMR binding experiments we also observed that compounds 1, 
3 and 4 weakly bind the DR5 receptor (Supplementary Figure 1). Noteworthy, compound 2 not only is 
the best binder for caspase 8, but, as shown below, together with compound 3, it is also the most effec-
tive compound in sensitizing Jurkat cancer cell line to TRAIL-induced cell death. Thus, our following 
experiments mainly focused on compound 2.
Figure 1. In silico discovery of small molecules that bind caspase 8 and their experimental effect on 
Jurkat cells survival; Zymogen caspase 8 interface region containing the small subunit (purple) was targeted 
and zymogen caspase 8 model (based on (PDB ID: 3H13)) was used as the receptor for in silico molecular 
docking studies. (a) Zymogen caspase 8 homodimer showing the interface region with one caspase 8 
monomer in surface representation and the other monomer in ribbon view. Different domains of the caspase 
8 are distinguished by color: large subunits are shown in grey and small subunits shown in purple and light 
blue. A grid box was introduced spanning whole interface region for the search space. (b) Compounds that 
experimentally sensitize Jurkat cells to TRAIL-induced apoptosis. Cell death/viability was evaluated in Jurkat 
cells by using an automated Trypan blue exclusion essay. Jurkat cells were treated with DMSO (control), 
TRAIL 7.5 ng/ml, the compounds (80 μM) and the combination, for 24 h, in 1% FBS. Results show that all 
four compounds sensitize Jurkat cells to TRAIL-induced cell death, with compounds 2 and 3 being the most 
effective. First compound can also induce significant cell death when used alone. (c) The 2D structures of 
the hit compounds 1-4, which were experimentally validated to sensitize Jurkat cells to TRAIL-induced cell 
death. (d ) 3D conformation of the hit compounds bound to caspase 8 interface region. Note: compound 1 
(cyan), compound 2 (gold), compound 3 Khaki and compound 4 (white). Right panel: enlarged boxed area 
of the left panel; C1 = compound 1; C2 = compound 2; C3 = compound 3; C4 = compound 4.
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Small molecule compound 2 (CaspPro) is an activator of caspase 8, potentiating TRAIL-induced 
caspase 8 activation in single cells and populations of cells. To further analyze if small molecule 
compound 2 can activate caspase 8 alone or in combination with TRAIL, we monitored caspase 8 activity 
by live cell microscopy, using a caspase 8 specific FRET reporter. We found that caspase 8 was activated 
faster and at higher levels when cells were stimulated by a combination of TRAIL and compound 2. 
Consequently, co-treatments with TRAIL and compound 2 together also resulted in greater cell death 
(96%), compared to TRAIL or compound 2 alone (20% and 1% respectively) (Fig. 3A–C). These results 
were subsequently confirmed in population of cells, by performing western blotting on the whole cell 
lysate. While activation of caspase 8 as measured by zymogen caspase 8 cleavage is not seen when cells 
are treated with compound 2 alone, compound 2 significantly promotes caspase 8 activation induced by 
TRAIL (Fig. 3D). Thus, this small molecule was named CaspPro. By using Jurkat leukemic cell lines defi-
cient in caspase 8, we could also confirm that caspase 8 is required for CaspPro-mediated potentiation 
of TRAIL-induced cell death (Supplementary Figure 2).
Small molecule CaspPro sensitizes K562 leukemic cells to TRAIL-induced caspase 3 activation 
and cell death. To further validate the effect of CaspPro in sensitizing cancer cells to TRAIL-induced 
cell death, we tested the compound in K562. This Bcr-Abl positive leukemic cell line is a highly resistant 
cell line to TRAIL action27. The underlying mechanisms of tumors cells resistance to TRAIL are not fully 
elucidated. Resistance can occur due to the dysregulation/deregulation of apoptotic signaling pathways, 
including the lack or decrease expression of the death receptors DR4 and DR5, and dysregulation of 
either pro-apoptotic or anti-apoptotic factors27. Our results demonstrate that only compounds 1 and 2 
are effective in sensitizing K562 cells to TRAIL-induced cell death, while compounds 3 and 4 do not 
show any effect. Interestingly, CaspPro is the most effective compound in sensitizing K562 resistant cells 
to TRAIL-induced cell death (Fig. 4A).
Furthermore, we determined that the combined regimens (compounds 1 or 2 in combination with 
TRAIL) resulted in pro-caspase 3 and PARP cleavage, implying apoptosis activation (Fig. 4B,C). While 
single treatments did not significantly change the morphology and number of the cells (except in the case 
of compound 1 when used alone, where some cells have apoptotic-like features), the combined treatment 
induced a change in morphology/shape and a decrease in the number of the cells (Fig. 4D).
Small molecule CaspPro sensitizes PC3 prostate cancer cells to TRAIL-induced caspase 
3 activation and cell death. Our results were further validated in PC3 prostate cancer cell line. 
Similar to the results obtained in K562 cells, CaspPro is the most effective in sensitizing PC3 cells to 
TRAIL-induced cell death, followed by compound 1, while the effects observed with compounds 3 and 
4 are smaller (Fig. 5A). Moreover, CaspPro sensitizes PC3 cells to TRAIL-induced caspase 3 activation 
and PARP cleavage (Fig. 5B), results also observed with compound 1 (Fig. 5C).
CaspPro can stabilize the caspase 8 homodimer interface. Using the experimentally determined 
structure of the caspase 8/cFLIP dimer (PDB 3H11), we created a model of the caspase 8 homodimer 
Figure 2. Compound 2 directly binds caspase 8. Small molecule compound 2 directly binds caspase 8, 
as determined by NMR. (a) extensive line broadening of compound 2 resonances caused by binding to the 
high molecular weight caspase 8. Line broadening is not observed in the control experiments in the presence 
of GST (b) or buffer alone (c).
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(Fig.  6A). We observed that including CaspPro in the preferred orientation while bound to monomer 
1, makes a number of favorable contacts with monomer 2, and thereby stabilizes the formation of the 
dimer. Specifically, the aromatic ring of CaspPro is within a hydrophobic pocket formed by L385, L 393, 
and F468 of monomer 2. Additionally, we propose hydrogen bonds between the sulfoxide oxygens of 
CaspPro and backbone amides of monomer 2. All of this interactions support the stabilization of the 
dimer.
Discussion
In silico screening has been used as a successful approach in finding inhibitors for several targets impli-
cated in different pathologies, including cancer28. These include the discovery of BRD4 (belongs to 
bromodomain family) inhibitors as therapeutics for acute myeloid leukemia, other malignancies and 
inflammatory diseases. Crystal structures of the in silico hits were later solved confirming their binding 
mode29.
Figure 3. Compound 2 (CaspPro) potentiates TRAIL-induced Caspase 8 activation in single cells (a-c) 
and in populations of cells (d). (a-c) FRET detection of caspase 8 activation in a time-lapse experiment 
within single living HeLa cells. Caspase 8 is activated faster and at higher levels by TRAIL when CaspPro 
(40 μM) is present, resulting in greater cell death. (d) K562 leukemic cells were treated with DMSO 
(control), 45 ng/ml TRAIL, 80 μM compounds 1, CaspPro and 4, and the combination, for 24 h, in 0.5% FBS, 
followed by western blot detection of the pro-caspase 8 and cleaved caspase 8. While 80 μM CaspPro alone 
can’t induce an increase in the cleaved caspase 8 (active caspase 8), CaspPro in combination with TRAIL 
increases TRAIL-induced caspase 8 activation. 80 μM compound 1 is able to induce some caspase 8 cleavage 
alone and can also increase the TRAIL-induced caspase 8 activation. 80 μM compound 4 does not have any 
effect on caspase 8 activation when used alone, and does not potentiate TRAIL-induced caspase 8 activation; 
Cleaved Caspase 8, Caspase 8 and β-Actin were detected on the same membrane, after stripping and 
reprobing the membrane. The blot images were cropped to show the proteins of interest; C1 = compound 1; 
C2 = compound 2 (CaspPro); C4 = compound 4.
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Our findings indicate that in silico screening can also be successfully used to identify small molecule 
activators of different targets, such as caspases, highlighting the importance of in silico screening as a 
vital aid in the initial drug discovery efforts of both inhibitors and activators small molecules. A recent 
study points out the identification of small molecules activators of the effector caspases 3 and 7, which 
act by increasing their zymogen’s proteolysis30. However, these small molecules are not direct activators 
of caspases, as demonstrated by a subsequent study31. CaspPro directly binds caspase 8 and potentiates 
TRAIL-induced caspase 8 activation in single cells and populations of cells, event followed by activation 
of caspase 3 and induction of cell death. A schematic representation of our findings and a proposed 
caspase 8 activation mechanism where CaspPro provides additional stabilization of the caspase 8 homod-
imer is shown in Fig. 6.
Figure 4. Compounds 2 (CaspPro) and 1 sensitize leukemic K562 cells to TRAIL-induced apoptosis. 
(a) K562 leukemic cells were treated with DMSO (control), 45 ng/ml TRAIL, 80 μM compounds 1-4, and 
the combination, for 24 h, in 0.5% FBS. Viability was measured by an automated Trypan Blue dye exclusion 
method. Results represent the mean +/- standard deviations (SDs) of 3 independent experiments, each one 
with multiple replicates. The results demonstrate that only compounds 1 and 2 are effective in sensitizing 
K562 cells to TRAIL-induced cell death, while compounds 3 and 4 do not show any effect at 80 μM. (b) 
K562 cells were treated with DMSO, 45 ng/ml TRAIL, 80 μM compounds 1 and 2, and the combination, 
for 24 h, followed by detection by western blot of the pro-caspase 3, cleaved caspase 3 and PARP cleavage 
(caspase mediated). The combined regimen resulted in pro-caspase 3 and PARP cleavage, implying caspase 
3 activation. (c.) K562 cells were treated with DMSO, 28 ng/ml TRAIL, 20 μM or 40 μM CaspPro, 40 μM 
compound 1, and the combination, for 24 h, followed by detection of the PARP cleavage. CaspPro at 20 μM 
and 40 μM, and compound 1 at 40 μM, sensitize K562 to TRAIL-induced PARP cleavage, indicative of 
caspase activation. (d) K562 leukemic cells were treated with DMSO, 45 ng/ml TRAIL, 80 μM compounds 1 
and 2, and the combination, for 24 h. Phase contrast microscope images of the untreated or treated cells are 
presented. A Nikon Eclipse TI-S Inverted Microscope was used (10X objective lens). While single treatments 
did not significantly change the morphology and number of the cells (except in the case of 80 μM compound 
1, where some cells have apoptotic-like features), the combined treatment induced morphological changes 
and a decrease cell number. β-Actin was used as an internal loading control. A total of three independent 
experiments were performed for each panel. All the proteins presented in a single panel (see b or c) were 
detected on the same membrane, by stripping and re-probing with a different antibody. The images of 
each membrane were cropped for showing the proteins of interest; experiments were done in 0.5% FBS; 
C1-4 = compounds 1-4.
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The pocket at the caspase dimerization interface of caspases has been successfully targeted to identify 
novel inhibitors14,15. These inhibitors suppress the caspase activation and apoptotic process. However, 
identification of small molecules that can stabilize the zymogen caspase 8 homodimerization and pro-
mote caspase 8 activation has a great potential for use in cancer therapy. Dimerized uncleavable chimeric 
caspase 8 constructs can be productively activated in vitro32. Other studies have shown that recombi-
nant caspase 8 containing the large and small subunits can be induced to dimerize by the addition of 
kosmotropic salts (e.g. 1 M sodium citrate), which maximally activates caspase 833,34. However, to our 
knowledge, small molecules that can stabilize the zymogen caspase 8 homodimerization and promote 
activation of caspase 8 when death receptors are activated have not been developed.
In our proposed model, CaspPro favors zymogen caspase 8 homodimerization that results in a pro-
ductive conformation initiating faster processing of mature caspase 8 when death receptors are engaged 
(Fig. 6A,B). CaspPro may provide additional stabilization of the caspase 8 homodimer which promotes 
caspase 8 activation after TRAIL treatment, leading to caspase-dependent cell death (Fig.  6C). Thus, 
although CaspPro alone can’t induce caspase 8 activation, it can significantly potentiate TRAIL-induced 
caspase 8 activation and cell death. The putative binding sites of CaspPro in the model structure of 
zymogen caspase 8 homodimer are shown in Fig. 6D. Additional experiments need to be performed to 
validate these CaspPro - zymogen caspase 8 putative binding sites in the future.
Our experimental validation results performed in multiple cell lines, such as leukemic Jurkat and 
K562 cells, and prostate PC3 cell line, revealed that CaspPro promotes caspase 8 activation, caspase 3 
activation and PARP cleavage, in the presence of TRAIL, leading to cell death. The development of meth-
ods for analyzing single living cell activity and signaling is critical for the advancement of a wide variety 
Figure 5. Compounds 1, 2 (CaspPro), 3 and 4 sensitize prostate cancer cells to TRAIL-induced apoptosis 
(a) PC3 prostate cancer cells were treated with DMSO (control), 10 ng/ml TRAIL, 80 μM Compounds 1-4 and 
the combination, for 24 h, in 0.5% FBS. Viability was measured by Trypan Blue dye exclusion method, using 
a TC10 Automated Cell Counter (Biorad, USA). The results represent the mean +/- standard deviations (SDs) 
of 3 independent experiments, each one with multiple replicates. Similar to the results obtained in K562 cells, 
compounds 1 and 2 are the most effective in sensitizing PC3 cells to TRAIL-induced cell death, while the 
effect observed with compounds 3 and 4 is smaller. (b) PC3 cells were treated with DMSO (control), 10 ng/
ml TRAIL, 80 μM CaspPro, and the combination, for 24 h, in 0.5% FBS, followed by detection by western blot 
of the pro-caspase 3, cleaved caspase 3 and PARP cleavage. The combined regimen resulted in pro-caspase 
and PARP cleavage, suggesting caspase 3 activation. This experiment was performed 3 times with similar 
results. (c.) PC3 cells were treated with DMSO (control), 10 ng/ml TRAIL, 40 μM compounds 1 and 2, and 
the combination, for 24 h, in 0.5% FBS, followed by detection of the cleaved caspase 3 by western blot. Both 
compounds 1 and 2 sensitize PC3 cells to TRAIL-induced caspase 3 activation. The blots presented in B and 
C were cropped and the proteins of interest are presented. Each membrane was stripped and re-probed with 
an antibody anti β-Actin, which is used as an internal loading control. The gels have been run under the same 
experimental conditions; C1-4 = compounds 1-4.
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of biomedical fields. By using a FRET detection of caspase 8 activation in a time-lapse experiment within 
single living cells, we were able to show that CaspPro promotes earlier and higher caspase 8 activation in 
single cells after TRAIL treatment, compared to TRAIL treatment alone.
Recent studies have shown that approximately 60% of cancer cell lines are resistant to TRAIL. Thus, 
sensitizing cancer cells to TRAIL-induced cell death is necessary35,36. We have shown that CaspPro can 
sensitize three different cancer cell lines (leukemic Jurkat and K562 cell lines, and prostate PC3 cell 
lines) to TRAIL-induced cell death. However, in order to obtain a comprehensive evaluation on CaspPro 
potential many more cancer cell lines and cancer mouse models have to be employed. The use of mouse 
models will also make possible CasPro’s safety profile evaluation.
Our findings establish a proof of concept strategy for discovery of novel small molecule activators or 
inhibitors of DISC related proteins, and a foundation for future development of caspase 8-selective small 
molecules that promote caspase 8 activation in response to death receptors stimulation.
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